Tag Archives: reimbursement

Prix Galien: Pharma R&D and Payers Need to Talk, Yesterday

R&D departments and payers need to communicate early in the drug development process: If pharma is a day late, then payers are likely to be a dollar short, according to panelists at the Galien Forum on Tuesday.
Posted in FDA, leadership, Market Access, pricing, R&D, Strategy | Also tagged , , , | Leave a comment

Value Isn't Just Dollars and Cents, says Pfizer Exec

Now that 90% of the top 43 countries for drug sales have instituted “significant” cost containment measures, it’s more important than ever to give payers the rest of the story, according to a Pfizer executive.
Posted in Europe, Global, healthcare, Market Access, Marketing, Patient Communication, pricing, Strategy | Tagged | Leave a comment

A Fine Line Between Regulation and Evolution

The strict regulatory divide between market authorization and price reimbursement is crumbling in the US. Ansis Helmanis asks — is industry prepared to adapt or challenge? On September 17, the FDA and CMS jointly issued a Federal Register (FR) notice that they were establishing a process for overlapping evaluations of premarket, FDA-regulated medical products when […]
Posted in FDA, Market Access, Regulatory | Also tagged , , , | Leave a comment

Wins and Losses from Risk-Sharing Agreements

Can you manage the external market impact? Risk-sharing agreements – where companies contract with reimbursement or assessment authorities to guarantee a new drug’s performance, often against specific outcomes measures, in return for access to patients – are among the latest innovations in managing health care costs. Use of the tool is standard in Australia, is […]
Posted in Europe, Global, healthcare, pricing, Regulatory, Strategy | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta